Rita Turpin

Company: University of Turku | Faron Pharmaceuticals

Job title: Postdoctoral Researcher

Seminars:

Exploring The Clever-1 Receptor Antibody as a Novel Mechanism to Target Macrophages in Cancer Treatment 10:30 am

Utilizing Bexmarilimab to target Clever-1, a novel mode-of-action to activate macrophage antigen presentation (ex vivo, spatial transcriptomics MATINS trial) Overcoming ICI resistance by targeting Clever-1 Exploring Clever-1 as a new player in hematological malignancies through the BEXMAB trialRead more

day: Conference Day One